Latest News and Events
Filter by
Selections
February 2, 2023
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Read MoreJanuary 9, 2023
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Read MoreDecember 21, 2022
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Read MoreDecember 21, 2022
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
Read MoreDecember 20, 2022
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
Read MoreDecember 15, 2022
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreDecember 8, 2022